Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Open accessAbstract
OBJECTIVES: Microglial overactivation, which is secondary to abnormalities of amyloid-beta peptide (Abeta) and tau proteins in the pathogenic cascade leading to onset of Alzheimer's disease (AD), accelerates tau pathology, according to our recent observations using mouse models of tauopathies, and this positive feedback results in formation of a vicious cycle between upstream and downstream processes, potentially hampering effective suppression of the entire cascade by anti-amyloid treatments. This motivates our present work aimed at dual monitoring of amyloidosis and microgliosis in living animal models of AD, toward therapeutic regulation of these two processes capable of halting the self-perpetuating cycle. METHODS: Transgenic mice expressing mutant amyloid precursor protein (APP23 mice) was examined by high-resolution positron emission tomography (PET) after administration of amyloid probe, Pittsburg Compound B (PIB) synthesized with high specific radioactivity (SA). Microglial activation in these mice was also imaged by PET and specific tracer, [(18)F]fluoroethyl-DAA1106. RESULTS: Progressive amyloidosis in APP23 mice was visualized by PET and high-SA PIB. In vitro assays revealed preferential binding of PIB to N-terminally modified Abeta, Abeta(N3pE). As levels of this Abeta subspecies in model mice are lower than those in AD patients, our findings plausibly explain advantages of high-SA tracers in sensitive detection of mouse amyloid. Near-simultaneous monitoring of amyloid removal and microgliosis in APP23 mice following injection of anti-Abeta antibody demonstrated positive correlation between levels of initially existing amyloid and antibody-induced microglial activation, suggesting the possibility of microglial overactivation in immunotherapy for subjects with abundant amyloid. CONCLUSIONS: The present animal imaging system would substantially facilitate establishment of a safe and effective therapeutic strategy targeting multiple key processes in the AD pathogenesis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PiB may bind preferentially to amyloid plaques containing pE3Aβ, and if other amyloid PET ligands do the same, this preferential binding might overestimate the extent of amyloid clearance.
“There are data that show that the amyloid PET ligand PiB may bind preferentially to amyloid plaques containing the pE3Aβ species 93,94 and although it is not known whether this is the case for other amyloid PET ligands, such preferential binding might over-estimate the extent of amyloid clearance.”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [93]
Cited by
Sorted by citations
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742 · see citing works
Maeda, J., Zhang, M.-R., Okauchi, T., Ji, B., Ono, M., Hattori, S., Kumata, K., Iwata, N., Saido, T. C., Trojanowski, J. Q., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3076-10.2011 · Cited by 136 · see citing works
Self-citationMicroglia in Aging and Alzheimer’s Disease: A Comparative Species Review
Edler, M. K., Mhatre-Winters, I., & Richardson, J. R. (2021) · Cells · doi:10.3390/cells10051138 · Cited by 126 · see citing works
Gulyás, B., Vas, Á., Tóth, M., Takano, A., Varrone, A., Cselényi, Z., Schain, M., Mattsson, P., & Halldin, C. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.02.020 · Cited by 94 · see citing works
A review of β-amyloid neuroimaging in Alzheimer's disease
Adlard, P. A., Tran, B. A., Finkelstein, D. I., Desmond, P. M., Johnston, L. A., Bush, A. I., & Egan, G. F. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00327 · Cited by 93 · see citing works
Imaging of cerebrovascular pathology in animal models of Alzheimer's disease
Klohs, J., Rudin, M., Shimshek, D. R., & Beckmann, N. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00032 · Cited by 82 · see citing works
Neurodegeneration and the neuroimmune system
El Khoury, J. (2010) · Nature Medicine · doi:10.1038/nm1210-1369 · Cited by 46 · see citing works
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27 · see citing works
- Authors
- Higuchi, M.
- Affiliations
- National Institute of Radiological Sciences (JP)
- Corresponding author
- Higuchi, Makoto
- ORCID
- Higuchi, Makoto
- Venue
- Current Alzheimer Research
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-04-01
- Volume
- 6
- Issue
- 2
- Pages
- 137-143
- ISSN
- 1567-2050 (ISSN-L)
- OpenAlex
- W1978902831
- Cited by
- 34
- References
- 0
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2016: 2 · 2015: 3 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- green
- repo.qst.go.jp
- Licence
- cc-by-nc-nd
- Locations
- Current Alzheimer Research (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- University of Pennsylvania
- Novartis Institutes for BioMedical Research
- RIKEN Brain Science Institute
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid-beta, microglial activation, amyloidosis, APP23 mice, Pittsburgh compound B, anti-amyloid immunotherapy, positron emission tomography, tau pathology
- MeSH terms
- Acetamides, Alzheimer Disease, Aniline Compounds, Animals, Autoradiography, Brain, Brain Mapping, Disease Models, Animal, Humans, Isotopes, Mice, Transgenic, Mutation, Phenyl Ethers, Protein Binding, Thiazoles, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, tau Proteins, Microglia, Positron-Emission Tomography, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review